ANSEM (the National Agency for Medicines and Health Products Safety), France’s Competent Authority, has granted Cohort Temporary Authorization for Use (ATUc) to GenSight Biologic’s LUMEVOQ®. LUMEVOQ® is a drug therapy designed to treat Leber Hereditary...
Fennec Pharmaceuticals has resubmitted their New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for PEDMARK™, a unique sodium thiosulfate formulation. PEDMARK is designed to prevent ototoxicity caused by cisplatin chemotherapy in patients under...
